Roche's KRAS G12C inhibitor divarasib outperforms Amgen and Bristol Myers Squibb drugs in Phase 3 head-to-head trial

Roche announced that its KRAS G12C inhibitor divarasib showed superiority over existing marketed therapies from Amgen and Bristol Myers Squibb in a Phase 3 head-to-head trial in lung cancer.

The trial directly compared the investigational drug with the two approved agents, and the data indicated a survival advantage for patients receiving divarasib. Full detailed results have not yet been released.

The positive readout positions Roche to potentially gain a new standard of care in KRAS‑mutated lung cancer, pending regulatory review and further data disclosure.